Presentation

The HiTS platform integrates a wide range of expertise and technologies necessary to accelerate the discovery of bioactive molecules using experimental screening (biochemical, in vitro, ex vivo) and in silico drug design strategies (chemoinformatics and molecular modeling).

Our objectives are to (1) aide in the discovery, characterization, and validation of novel molecular targets, (2) translate validated targets to actionable drug discovery systems, (3) identify, validate and develop novel bioactive molecules for preclinical and clinical development programs in oncology. The platform is open to the scientific community and can support research projects on a collaborative or service basis.

High-Throughput Screening

The platform offers its collaborators access to a robotic high-throughput screening facility, featuring cutting-edge equipment:

• Assay automation: a robotic centrifuge, and a high-performance multi-mode reader (capable of fluorescence, absorbance, and luminescence measurements in up to 1536 well plates), a versatile high-volume dispensing robot, and integration by an Access robotic arm.
• The screening platform is configured to maximize experiment automation, data quality and robustness, and the efficiency of data generation. Our state-of-the-art services provide the necessary tools to overcome scientific challenges encountered during the early development of innovative oncology products.

Molecular Modeling for Drug Design

The HiTS platform uniquely integrates high-throughput screening (HTS) expertise with chemoinformatics and molecular modeling, managed by Philippe Roche (from the INT-3D platform). As a result, we offer a comprehensive range of services, including chemical library management and post-screening chemoinformatic analyses, allowing users to perform cost-effective SAR (Structure–Activity Relationship) studies based on available commercial analogs and ready-to-synthesize commercial libraries. Following our rigorous hit validation procedure, the platform facilitates the transition to the "hit-to-lead" phase, all within the same infrastructure.